Ciljevi
Evaluate real-world progression-free survival
Voditelj obrade
Intergroupe Francophone de Cancérologie Thoracique (IFCT)
Kategorije korištenih podataka
Données d’identification (sans donnée nominative) / Données de santé
Origine de données utilisées
Soins
Institut de Cancérologie de l'Ouest (Nantes et Angers)
Populacija koja je predmet istraživanja ili obrade podataka
Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib • Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed) • Patients who received at least one dose of the treatment with sotorasib as part of the French Early Access Program (ATU program) • Patients who were informed about the study and do not object for their data to be collected • Age > 18 years
Pravna osnova
Intérêt public
Interni i vanjski primatelji podataka
IFCT
Datum početka istraživanja
24/03/2022
Razdoblje čuvanja podataka
Durée conforme à la réglementation